Non-dilutive, revenue-linked, and a valuation that doubled in a hundred and fifty days — the tape got weird before lunch. A little context before today's news: AI money's been clustering around companies pitching foundational leverage — model platforms, infrastructure, applied tooling, physical AI, sovereign AI. We've already seen it with Meshy, Arrakis, Fly.io, Enigma, and Multiverse Computing. And Moonshot AI, which closed three and a half billion at a thirty-five billion post, is now sounding out investors on a follow-on at a fifty billion pre. This is Startup Fundraising, with a strange mix today: prevention, networking chips, even synthetic users. Function Health's four-fifty is structured so General Catalyst only wins if the revenue shows up. Let's start there. Tech Funding News, with Abhinaya Prabhu:
Function secures $450M in growth financing from General Catalyst’s Customer Value Fund. - The Austin startup says it has 500,000+ members and 100M+ completed lab tests since 2023. - It follows Function’s acquisitions of Getlabs and SuppCo, expanding its bundled approach to prevention.
Function Health pulls $450 million from General Catalyst through GC's Customer Value Fund. Read the fine print: the deal is revenue-linked growth financing, billed as non-dilutive, with no equity in the structure. Okay, now that's a structure I actually want to look at. GC only gets paid if Function's revenue performs, so they're underwriting 500,000 members and 100 million lab tests holding up. The preventive-care slogan is beside the point. And here's what caught my eye: this is General Catalyst's third move in four days, with a different instrument each time. It co-led a medtech seed, showed up on a cap table, and now it's the sole backer of a revenue-linked deal. One firm, three capital structures in a week. 'Non-dilutive' makes for a great headline. I want to see the repayment waterfall — what happens if test volume stalls? And are the Getlabs and SuppCo acquisitions folded into what GC is lending against, or is that a separate line? Exactly — 'non-dilutive' only holds if the growth targets get hit. Miss them, and I'd bet there's a conversion trigger or a warrant hiding in there somewhere. But credit where it's due — of everything that raised this week, this one at least shows you where the money goes. It's tied to retention and repeat testing, which gives me an actual business to underwrite. Here's SiliconANGLE:
Israeli network chip startup Xsight Labs Ltd. said today it has closed on a$300 million funding round that brings its valuation to $2.8 billion. It’s planning to use the funds to help its programmable Ethernet switches and 800-gigabit data processing units push deeper into cloud and artificial intelligence networks.
Xsight Labs closed $300 million at $2.8 billion, and the name to circle is Fidelity, the lead. SiliconANGLE had it first. When Fidelity runs point on a private infrastructure round, someone's usually already sketching an IPO timeline. Fidelity's joined by T. Rowe, Artisan, Maverick, Battery, and Intel Capital. That's a crossover roster stacked around a Tel Aviv chip company. Public-markets money doesn't show up early for the vibes. Okay, but this one I actually like, because there's silicon. E1 DPU, X2 switch, under 200 watts for a 12.8-terabit switch — give me a number I can measure. My hesitation, though: the whole bet is on a $150 billion networking market by 2028, per SiliconANGLE. Xsight is walking into Broadcom and Nvidia's networking backyard. So is this $300 million additive, or is it funding a fight with two incumbents that own the switch fabric today? The Ultra Ethernet Consortium standards they're chasing give Xsight exactly the open-standard opening a challenger needs. But the whole deal rides on whether they land the 'tier-1 customers' they're name-dropping. After the Function Health structure we just walked through, this is refreshing — at least I can see where the money goes. Fab capacity, engineering headcount, supply chain. Real costs for a real chip. Abhinaya Prabhu, writing in Tech Funding News:
Simile has raised $200 million in Series B funding, reaching a $2 billion valuation just five months after closing its $100 million Series A. - Founded by Stanford PhD graduate Joon Sung Park alongside Michael Bernstein, Percy Liang and Lainie Yallen, the company develops foundation models that simulate human behaviour for businesses.
Simile raised $100M in its Series A this spring. Now it's raised a $200M Series B at $2 billion. The valuation doubled in roughly a hundred and fifty days, with Greenoaks leading. I keep coming back to Greenoaks writing a $200M check into a round twice the size of the last one. That's a lot of conviction in a valuation that doubled just five months after the Series A. Okay, but "foundation models that simulate human behavior" — that sentence has been in every deck I've read this week. Predict what humans do before they do it. Sure. Here's where I stop nodding: CVS, Wealthfront, Deloitte, Gallup on the logo wall. Fine. But what does Deloitte pay, and what happens the first time the model tells them customers will do one thing and they do the opposite? I want the churn number, not the Stanford pedigree. Simile isn't alone here. TechCrunch clocked a whole class of AI unicorns doubling their valuations before the last round's cap table even settles. Simile just did it faster than most. The founding team's paper on this is famous, and the marquee customers look great. Greenoaks money helps too. Sure, it buys the meeting. It still doesn't buy me ARR I can see. Katie Roof, Rya Jetha, writing in Business Insider:
The hottest trade in venture capital may no longer be chatbots—it's robots. Robotics startup General AI is raising money in a round that could value it at 50% more than just a month ago, say people familiar with the deal. The discussions Generalist AI is holding with investors would value the company at $3 billion.
So we asked whether this robotics round would actually close, and at what number. Now the answer's moving in real time: three billion, up fifty percent from a month ago, and the ink isn't even dry. 8VC is expected to lead, per Business Insider. That's the part I'm watching. A lead willing to reprice you fifty percent in thirty days is either seeing something in the product or pricing the narrative. The piece says the hottest trade has shifted from chatbots to robots. Fine — but a robotics foundation model doesn't have an inference meter running like an LLM does. So what supports a three-billion multiple? A fifty percent jump in a month, Adam, is the same cap table getting repriced by a different set of hands. Right. Put that next to the Function Health structure we just hit: General Catalyst only wins if the revenue shows up. Here, nobody's told me what the money buys yet. Here's what Tech.eu is reporting. Agon. Thirty million, British defence, virtual battlefields to train against drone swarms. After a week of billion-dollar decks, this is the one I actually want to sit with. Thirty million is a rounding error next to Function Health's four-fifty — but the use case here is concrete: counter-drone training simulation. You know exactly what the check buys. That's the whole point. Ukraine turned cheap drones into a real threat, and you can't train pilots against ten thousand of them in a field. So you build the field in software. The money goes into the sim engine and the data — I can follow that dollar. A $30M seed at launch says the founders came in with pedigree behind the pitch. Defence procurement is patient money, too. Land one MoD contract, and they'll have real revenue to build on. Right. Stack it against the tape: fusion renderings and human-behavior models that promise to predict everyone. This one has a customer with a budget and a problem that's already killing people. Unsexy, maybe, but real — and sold. If Startup Fundraising helps you stay informed, subscribe and leave a review wherever you’re listening. Reviews help other founders and investors find the show, and we appreciate your support.
You’ll find links to every story in today’s show notes, so take a look if you want to dig deeper. That’s Startup Fundraising for today. This is a Lantern Podcast.